| 381.17 Delayed Data As of Dec 14 |  +2.66 / +0.70%Today’s Change | 281.89 Today|||52-Week Range 416.49 | +1.39% Year-to-Date |
| Goldman Sachs Takes Action on Pharma Stocks Dec 14 / GuruFocus News - Paid Partner Content | 4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Dec 11 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regenero... Dec 12 / Zacks.com - Paid Partner Content | Why Is Regeneron (REGN) Up 2.4% Since Last Earnings Report? Dec 06 / Zacks.com - Paid Partner Content |
| Previous close | 378.51 |
| Today’s open | 382.96 |
| Day’s range | 379.00 - 386.90 |
| Volume | 758,430 |
| Average volume (3 months) | 702,254 |
| Market cap | $36.5B |
| Earnings growth (last year) | +31.81% |
| Earnings growth (this year) | +32.38% |
| Earnings growth (next 5 years) | +13.00% |
| Revenue growth (last year) | +20.82% |
| P/E ratio | 24.4 |
| Price/Sales | 7.42 |
| Price/Book | 6.01 |
| Today’s change | Today’s % change | |
|---|---|---|
| BAXBaxter International... | -1.25 | -1.87% |
| VRTXVertex Pharmaceutica... | -3.36 | -1.94% |
| ZTSZoetis Inc | -2.49 | -2.74% |
| ALXNAlexion Pharmaceutic... | -3.00 | -2.67% |
| Next reporting date | February 12, 2019 |
| EPS forecast (this quarter) | $5.54 |
| Annual revenue (last year) | $5.9B |
| Annual profit (last year) | $1.2B |
| Net profit margin | 20.41% |
Sector Health Technology |
Industry Biotechnology |
Co-President, Chief Executive Officer & Director Leonard S. Schleifer |
Co-President, Director & Chief Scientific Officer George Damis Yancopoulos |
Corporate headquarters Tarrytown, New York |
